22nd Century Group Inc (XXII)

[MinnieM]

Evaluating New Nicotine Standards for Cigarettes
http://www.fda.gov/TobaccoProducts/PublicHealthScienceResearch/Research/ucm405250.htm

Principal Investigator: Eric C. Donny
Funding Mechanism: National Institutes of Health- Grant
ID number: 1U54 DA031659-01
Award Date: 9/15/2011
Institution: University of Pittsburgh at Pittsburgh

Reduction in nicotine content has been proposed as a potential regulatory measure to render cigarettes non-addictive and, consequently, to reduce smoke exposure and improve public health. The goal of this research effort is to determine how a marked reduction in the nicotine content of cigarettes impacts the use and effects of tobacco in current smokers. This five-year research effort involves four interrelated projects. Project 1, a multisite trial, includes two human studies evaluating the dose-response relationship for nicotine yield within the range thought to be at or below threshold for dependence and the potential use of concurrent nicotine replacement therapy (NRT) to facilitate the transition to very low nicotine content (VLNC) cigarettes; study subjects include 1,080 daily smokers aged 18 and older. Project 2, a multi-site trial involving 1,250 subjects, assesses the effects of prolonged VLNC use and compares an immediate switch to VLNC cigarettes with a gradual reduction in cigarette nicotine content over 20 weeks. Project 3 focuses on the impact of VLNC cigarettes on smokers with schizophrenia; this project begins to address an important concern about the impact of a new nicotine content standard in smoker sub-populations who might be particularly vulnerable to the effects of nicotine reduction. Project 4 addresses concerns that the manipulation of other tobacco constituents could offset the predicted gains of VLNC cigarettes by investigating the relationship between the threshold dose for maintaining rat nicotine self-administration and the presence of minor alkaloids, beta-carbolines, acetaldehyde, and monoamine oxidase inhibitors (MAOIs). These four projects will reveal important information about whether establishing new lower nicotine standards for cigarettes would reduce cigarette use and, consequently, reduce the morbidity and mortality associated with smoking.

Results of this project can be found here:
http://www.projectreporter.nih.gov/project_info_results.cfm?aid=8650430&icde=17197897

I don't have time to read all of the related articles published in the science journals. Hopefully, someone else has time. But, it seems like there has been quite a bit published on this study.








In Reply to 'ChairmanoftheBored'
Interesting video found on FDA.gov regarding some of the research being done with XXII technology- Video: http://www.fda.gov/TobaccoProducts/PublicHealthScienceResearch/ucm442633.htm

While the chart is still fighting long-term resistance from Oct '14, a close above .94 should trigger a technical buy signal (Bullish Harami Cross).

IMO XXII will be achieve at least $3-5M in quarterly sales by year's end or Q1 2016. Until that time, I do not foresee cash on-hand needed to fund day-to-day operations as being a significantly dilutive factor, if at all. I would expect the bulk of any offerings to be taken from the Shelf and used for ventures that only add value to the Company.

GO XXII!